Correvio Pharma

$0.4075
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.005 (+1.28%) Today
+$0.0125 (+3.16%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell CORV and other stocks, options, ETFs, and crypto commission-free!

About CORV

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. Read More The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients, and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Employees
138
Headquarters
Vancouver, British Columbia
Founded
1986
Market Cap
19.53M
Price-Earnings Ratio
0.00
Dividend Yield
0.00
Average Volume
7.34M
High Today
$0.40
Low Today
$0.3711
Open Price
$0.40
Volume
6.50M
52 Week High
$4.44
52 Week Low
$0.3711

Collections

CORV News

ReutersDec 11

Correvio Pharma to explore sale after FDA panel setback, shares plunge

(Reuters) - Correvio Pharma Corp on Wednesday said it would explore options including putting itself up for sale, a day after a panel of experts advising the U.
266
MarketWatchDec 11

Correvio Pharma to consider a sale after FDA adcomm vote

Shares of Correvio Pharma CORV, +7.69% tumbled 54% in premarket trading after the specialty drugmaker said it was considering a sale of the company or its asset
658
BenzingaDec 10

Correvio Pharma In The Spotlight Ahead of Brinavess Adcom Verdict

Correvio Pharma Corp (NASDAQ: CORV) shares came under selling pressure Friday after a briefing document released ahead of the company's planned Adcom meeting sh
535

CORV Earnings

-$0.37
-$0.27
-$0.17
-$0.07
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Mar 11, Pre-Market

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.
Search
LearnBlogCareersHelpLog InSign Up